News

A tough economy is weighing on growth.

Takeda Pharmaceutical Co Ltd (NYSE:TAK) stock is trading higher on Wednesday. Earlier today, the European Commission approved Takeda’s Adzynma (recombinant ADAMTS13) for treating ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). Congenital thrombotic thrombocytopenic purpura, also known as Upshaw-Schulman syndrome, is a rare inherited disorder that affects the blood’s ability to clot properly. This condition leads to the excessive form

Investors bought the beaten-down infrastructure stock ahead of earnings.

Axon Enterprise's second-quarter sales jumped and the TASER maker raised its full-year guidance on demand for its services.